the voice of the small-medium (SME) BioPharmaceutical Industry

EMIG companies

work with the NHS to allow patients to choose where they receive their medical care

EMIG Members

provide 40% - 50% of the branded medicines used by the NHS

80% of

pharmaceutical innovation is generated by small-medium companies

EMIG Membership

exceeds 250 companies and organisations - less than 10% are represented by another trade body

90% of

pharmaceutical companies in the UK are small-medium sized companies


EMIG is the UK research-based trade association that represents the interests of small to medium-sized BioPharmaceutical companies (SMEs).

EMIG member companies range from start-ups, whose prime focus is R&D, to highly developed businesses delivering essential products to patients, while continuing to invest heavily in the fight against disease.

EMIG has over 260 Members, of which, only c. 10% are members of other trade bodies. Consequently, EMIG is the sole representative body for c. 50% of the UK branded medicines industry.

EMIG Launches Paper on the Interests of the UK in the Context of Brexit:

'Assuring the Interests of the UK in Global Pharmaceuticals - What role does the EU play?'

EMIG Paper on Opportunities for UK Healthcare Post Brexit:

'UK BioPharma - Adapting to a changing landscape to deliver a better global future'

Executive Summary

'UK BioPharma - Adapting to a changing landscape to deliver a better global future'

Full Paper

The paper was presented to the EMIG Membership at the EMIG Quarterly Meeting in central London on Monday 5th September.

The full UK Data Science Report is available on this website.

For enquiries regarding the paper, please contact:

Leslie Galloway 

Cookie Policy | Terms and Conditions | Privacy Policy
Copyright © Ethical Medicines Industry Group 2013 | Ethical Medicines Industry Group (EMIG), 120 Pall Mall, London SW1Y 5EA